Table 3.
Association between the levels at baseline serum of sNKG2DLs and the OS of melanoma patients.
| sNKG2DLs a | Immune checkpoint treatment b | OS c | pd | Control e | OS | p | ||
|---|---|---|---|---|---|---|---|---|
| Baseline | ||||||||
| MICA | + | 22 | 12.5 | 0.45 | 19 | 15.6 | 0.94 | |
| − | 172 | 16.4 | 46 | 12.0 | ||||
| MICB | + | 43 | 8.8 | 0.02 | 25 | 13 | 0.4 | |
| − | 151 | 21.6 | 40 | 12 | ||||
| ULBP-1 | + | 85 | 12.1 | 0.01 | 36 | 15.6 | 0.85 | |
| − | 78 | 25.3 | 29 | 8.5 | ||||
| ULBP-2 | + | 45 | 9.8 | 0.11 | 9 | 15.6 | 0.77 | |
| − | 149 | 20.2 | 56 | 12 | ||||
| ULBP-3 | + | 77 | 13.8 | 0.10 | 25 | 16 | 0.65 | |
| − | 117 | 16.7 | 40 | 11.2 | ||||
| W12 | ||||||||
| MICA | + | 22 | 12.4 | 0.02 | 11f | 11.1 | 0.18 | |
| − | 159 | 20.2 | 13 | n.r. | ||||
| MICB | + | 54 | 10.4 | 0.01 | 11 | n.r. | 0.05 | |
| − | 127 | 22.8 | 12 | 11.0 | ||||
| ULBP-1 | + | 80 | 14.7 | 0.17 | 13 | 11.1 | 0.14 | |
| − | 70 | 26.3 | 10 | n.r. | ||||
| ULBP-2 | + | 49 | 14.7 | 0.27 | 5 | 15.6 | 0.82 | |
| − | 132 | 21.6 | 12 | 24.3 | ||||
| ULBP-3 | + | 70 | 16.8 | 0.57 | 5 | n.r. | 0.49 | |
| − | 106 | 16.7 | 18 | 13.1 | ||||
a
: detection of sNKG2DLs (MICA, MICB, ULBP-1, 2, 3) in the pre- (baseline) or post- (W12) treatment serum of melanoma patients; positive (+) or negative (−) measurement (ng/mL) of sNKG2DLs are indicated;
b
: number of subjects from the cohort of patients treated with immune checkpoint blockade agents;
c
: OS: median overall survival expressed as months;
d
: p value obtained from log-rank test analysis;
e
: Number of patients from the control cohort.
f
: W12 post-treatment data from melanoma patients treated with BRAFi; n.r. = not reached. Post-treatment from patients treated with standard therapies was not available.